Breast Cancer

Dr. Wassim Mchayleh on ASCENT-03: Evaluating Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer

From Podium To Practice – Breast Cancer ESMO Part 1 In this overview, Dr. Wassim Mchayleh breaks down the ASCENT-03 trial, highlighting the rationale for...

Latest Post

Dr. Wassim Mchayleh on TROPION-Breast02: Evaluating Dato-DxD in Metastatic Breast Cancer

From Podium To Practice – Breast Cancer ESMO Part 2 In this segment, Dr. Wassim...

Dr. Wassim Mchayleh on VIKTORIA-1: Gedatolisib Combinations in HR+/HER2- Metastatic Breast Cancer

From Podium To Practice – Breast Cancer ESMO Part 3 In this overview, Dr. Wassim...

Dr. Wassim Mchayleh on evERA: Exploring Elacestrant Combinations in ER+/HER2– Metastatic Breast Cancer

From Podium To Practice – Breast Cancer ESMO Part 4 In this overview, Dr. Wassim...

Dr. Sara Tolaney & Dr. Wassim Mchayleh on Trial Design & Patient Populations in ASCENT-03 and TROPION-Breast02

From Podium To Practice – Breast Cancer ESMO Part 5 In this discussion, Dr. Wassim...

Interpreting Efficacy & Ethical Design: Drs. Tolaney and Mchayleh on ORR, PFS, OS & Crossover Strategy

From Podium To Practice – Breast Cancer ESMO Part 6 In this discussion, Dr. Wassim...

Crossover & Survival Implications: Drs. Sara Tolaney and Wassim Mchayleh on ASCENT-03 vs TROPION-Breast02

From Podium To Practice – Breast Cancer ESMO Part 7 In this segment, Dr. Wassim...

Managing Challenging Toxicities: Drs. Sara Tolaney & Wassim Mchayleh on Safety Considerations for SG and Dato-DXd

From Podium To Practice – Breast Cancer ESMO Part 8 In this discussion, Dr. Wassim...

Where Are We Going With ADCs in TNBC? Insights from Drs. Sara Tolaney & Wassim Mchayleh

From Podium To Practice – Breast Cancer ESMO Part 9 In this forward-looking discussion, Dr....